Metax Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 21-12-2024
- Paid Up Capital ₹ 3.12 Cr
as on 21-12-2024
- Company Age 24 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.50 Cr
as on 21-12-2024
- Satisfied Charges ₹ 41.35 Cr
as on 21-12-2024
- Revenue %
(FY 2020)
- Profit 8.09%
(FY 2020)
- Ebitda
- Net Worth -2.74%
(FY 2020)
- Total Assets -1.40%
(FY 2020)
About Metax Life Sciences
The Corporate was formerly known as Mantena Drugs Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 3.12 Cr.
The company currently has active open charges totaling ₹4.50 Cr. The company has closed loans amounting to ₹41.35 Cr, as per Ministry of Corporate Affairs (MCA) records.
Shiv Charan, Bharti Agarwal, Pushpa Bai, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24230TG2000PLC035486
- Company No.
035486
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
17 Oct 2000
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Metax Life Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashish Kumar  | Managing Director | 09-May-2024 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Neel Chhetri | Director | 08-Jul-2024 | Current |
| Shiv Charan | Director | 09-May-2024 | Current |
| Bharti Agarwal | Director | 09-May-2024 | Current |
| Pushpa Bai | Director | 09-May-2024 | Current |
Financial Performance of Metax Life Sciences.
Mantena Laboratories Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 8.09% increase in profit. The company's net worth dipped by a decrease of 2.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Metax Life Sciences?
In 2020, Metax Life Sciences had a promoter holding of 57.16% and a public holding of 42.83%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sibin Ventures Private LimitedActive 6 years 2 monthsAshish Kumar and Neel Chhetri are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of Maharashtra Creation Date: 29 Sep 2011 | ₹4.50 Cr | Open |
Edelweiss Asset Reconstruction Company Limited Creation Date: 07 Mar 2010 | - | Open |
Others Creation Date: 17 Mar 2011 | ₹2.00 Cr | Satisfied |
How Many Employees Work at Metax Life Sciences?
Unlock and access historical data on people associated with Metax Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Metax Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Metax Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
